Trials / Completed

CompletedNCT04241965

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870

A Phase 1b, Single-blind, Placebo-controlled, Adaptive Design, Outpatient Trial to Assess the Effects of Single Oral Tablet Doses of OPC-214870 on Photic-induced Paroxysmal Electroencephalogram Responses in Subjects Who Have Demonstrated Photoepileptiform Discharges on Electroencephalogram With or Without Seizures

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 16 (actual)

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
Sex: All
Age: 18 Years – 64 Years
Healthy volunteers: Not accepted

Summary

Despite availability of several antiepileptic drugs (AEDs), in one-third of patients, epilepsy remains uncontrolled with AEDs. There is a need to develop new approaches to improve the existing medications to relieve patients' epilepsy, and OPC-214870 is being studied for this purpose.

Conditions

Epilepsy

Interventions

Type	Name	Description
DRUG	OPC-214870	Tablet(s)
OTHER	Placebo	Tablet(s)

Timeline

Start date: 2020-02-18
Primary completion: 2021-10-11
Completion: 2021-10-28
First posted: 2020-01-27
Last updated: 2022-08-24

Locations

1 site across 1 country: United States

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT04241965. Inclusion in this directory is not an endorsement.